QIAGEN N.V. (QGEN) announced the launch of QIAstat-Dx Gastrointestinal Panel 2 in the United States following the recent FDA clearance of the syndromic test for use in clinical settings. The launch marks a significant step forward in improving the accuracy and efficiency of gastrointestinal (GI) infection diagnosis. The latest development from QIAGEN addresses the major challenges of the diagnosis of overlapping symptoms and laborious testing methods in treating GI infections. This should also strengthen th ...